Cancer is undoubtedly one of the deadliest diseases our generation is witnessing today. According to WHO, it is the second leading cause of death globally. Although there has been continuous research on cancer treatments across the globe, the number of patients losing their lives due to cancer does not seem to reduce in the same proportion. The primary reason behind this is that traditional drug development focuses more on delaying the disease progression in cancer rather than finding a cure.
Amid the plethora of companies providing traditional drug development, a company like Chimeric Therapeutics is distinguishing itself by serving cancer patients with novel cell therapies. Listed on the ASX in early 2021, Chimeric Therapeutics is recognized as a pioneer in cell therapy treatment and is the leading cell therapy company on the ASX. The Australian-based company is Chaired by Paul Hopper (Founder ) and the CEO is ex-Kite senior executive, Jennifer Chow.
The team of Content Atwork had the opportunity to engage in a fascinating conversation with Paul, in which he shed light upon Chimeric Therapeutics’ establishment journey as well as the innovative services and solutions offered by the company. Here are some excerpts from the conversation:
I formed the Company around CAR T technology developed at the City of Hope Cancer Centre in California where we are now progressing a Phase 1 clinical trial in glioblastoma.
Since listing on the ASX we have increased the technology pipeline with acquisitions from the University of Pennsylvania and Case Western University Our mission is more ambitious than delaying disease progression in cancer. We believe that novel cell therapies have the promise to cure cancer. Our mission is to bring that promise to life for more patients with cancer by discovering, developing, and commercializing cell therapies with the most curative potential.
Chimeric is the leader in cell therapy on the ASX (Australian Securities Exchange). We believe that we can change the course of history for more patients with cancer. Our oncology pipeline includes,
Our company is mainly built around five core values which include,
At the helm of the company, I serve as the Founder and Executive Chairman. I have been behind a number of successful biotech companies, both in America and Australia. I am well-known for Viraltyics which was acquired by Merck in 2018 for $500 million. My other ventures include a $3 billion company Imugene (ASX: IMU) and Radiopharm Theranostics (ASX: RAD) which was listed on the Australian Stock Exchange in November 2021.
I founded Radiopharm Theranostics based on four novel radiopharmaceutical technologies from leading European and US institutions, and which has the ambition of becoming a recognized leader in the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs,
Chimeric Therapeutics is led by a team of cell therapy pioneers and experts who are committed to bringing the promise of cell therapy to life for more patients with cancer. The team , led so ably by our CEO Jennifer Chow, have worked on four of the five approved CAR T druhs globally. Their collective experience in cell therapy development and commercialization makes Chimeric uniquely positioned to translate innovative science into curative therapies for patients. Our Scientific Advisory Boards connect us with world leaders and keep us up to date and relevant in the industry.
I always tell my wife I am surrounded by geniuses and everyday is such a privilege working and learning from the best minds in the life sciences/biotechnology space. When I search for my team, I look for people with deep experience and connections in the field and those who have taken drugs from bench-to-bedside or had significant success to date in clinical trials.
We have been very fortunate in that we have not been greatly affected by COVID. Apart from limitations on travel to conferences or team meetings, our work has continued in a business as usual fashion. Our mantra is our mission and this is what drives our entire team through any situation—“Our mission is to bring that promise to life for more patients with cancer by discovering, developing, and commercializing cell therapies with the most curative potential.”
We have just announced the transformative portfolio expansion of the CORE-NK platform—a clinically validated, off-the-shelf natural killer cell platform. This platform will triple our current portfolio by enabling us to accelerate the development of multiple new NK cell assets that work in perfect synergy with our existing pipeline. This is going to be a very interesting space in life sciences to keep an eye on.